KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other financing activities: 2009-2024

Historic Other financing activities for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Dec 2024 value amounting to -$94,000.

  • Biomarin Pharmaceutical's Other financing activities fell 108.89% to -$94,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$3.2 million, marking a year-over-year decrease of 19.12%. This contributed to the annual value of -$3.2 million for FY2024, which is 38.98% down from last year.
  • As of Q4 2024, Biomarin Pharmaceutical's Other financing activities stood at -$94,000, which was up 96.89% from -$3.0 million recorded in Q3 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Other financing activities peaked at $943,000 during Q2 2020, and registered a low of -$3.0 million during Q3 2024.
  • For the 3-year period, Biomarin Pharmaceutical's Other financing activities averaged around -$971,167, with its median value being -$69,500 (2023).
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 240.12% in 2020, then slumped by 86,933.33% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Other financing activities (Quarterly) stood at $943,000 in 2020, then dropped by 25.45% to $3,000 in 2021, then crashed by 86,933.33% to -$2.6 million in 2022, then spiked by 98.27% to -$45,000 in 2023, then plummeted by 108.89% to -$94,000 in 2024.
  • Its Other financing activities stands at -$94,000 for Q4 2024, versus -$3.0 million for Q3 2024 and -$18,000 for Q2 2024.